Gilead Sciences, Inc. (GILD) fundamentals from SEC filings — revenue $29.4B, net margin 28.9%, diluted EPS $6.78 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Net income | $6.2B | $4.6B | $5.7B | $480.0M | $8.5B |
| Net margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Free cash flow | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home